SOURCE: CNS Response

CNS Response

May 27, 2011 10:15 ET

CNS Response Approved for New Patents in U.S. and Canada for Innovative Analytic Tools for Mental Health

ALISO VIEJO, CA--(Marketwire - May 27, 2011) - CNS Response, Inc. (OTCBB: CNSO) announced today that the company's first Canadian patent and fifth U.S. patent applications have been approved. The patents provide further protection for the company's neurophysiology-based database and analytic tools, which provide medical professionals with information correlating medication response for patients being treated for mental disorders. The two new patents are expected to be issued by mid June.

"CNS Response continues to expand and improve our innovative analytic tools for mental health treatment," said George Carpenter, CNS Response CEO. "These additional patents reflect our ongoing research and development efforts, as well as our commitment to the Canadian healthcare market."

US Patent Application No. 12/273,383, entitled "Methods Of Recommending Neurophysiological Therapies," was approved in April and is expected to be issued by the United States Patent and Trademark Office within a few weeks. Canadian Patent Application No. 2,399,482, entitled "Method for Classifying and Treating Physiologic Brain Imbalances Using Quantitative EEG," is expected to be issued by the Canadian Intellectual Property Office by mid June.

The patents build on CNS Response's original physician-developed database, Referenced-EEG® (rEEG®), and are part of the company's new Psychiatric EEG Evaluation Registry, or PEEROnline™, a cloud-based platform which allows physicians to exchange outcome data referenced to their patients' neurophysiology.

Finding the right medication for an individual patient suffering from mental health issues is one of the biggest challenges facing medical professionals. The PEER Online service will allow physicians to compare and learn which medication treatments have been effective, and which have been ineffective for their peers treating patients with similar neurophysiology.

Medical professionals interested in learning more can contact CNS Response at PEERinfo@cnsresponse.com.

About CNS Response
CNS Response provides reference data and analytic tools for clinicians and researchers through PEER Online, a new registry and reporting platform. The registry builds on the company's original physician-developed database called Referenced-EEG® (rEEG®). Developed with clinical data supplied by physicians, PEER Online serves as a platform for medical professionals to exchange treatment outcome data referenced to objective neurophysiology data from EEG. Physicians using this information have consistently reported reduction in their use of trial and error pharmacotherapy. To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.cnsresponse.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

Contact Information

  • Investor Relations:
    Marty Tullio
    Managing Partner
    McCloud Communications, LLC
    949.553.9748
    Email Contact

    Media Relations:
    Joyce Johannson
    Johannson Communications
    612.927.4543 (office)
    612.845.3080 (cell)
    Email Contact